Multimodality Therapy for Gastric Cancer : Appendix: Database of the Cancer Institute Hospital

Recent clinical trials of adjuvant therapy for gastric cancer in Japan have shown improved survival benefits, but the results have been considered controversial and have been viewed with some skepticism in the West. Until now, the efforts of Japanese surgical oncologists in multimodality therapy have not been fully understood because they have not been adequately reported in English. This volume now presents the experience and expertise of Japanese surgeons who utilize preoperative or intraoperative chemotherapy, or a combination of systemic and regional chemotherapy. Their collected work provides valuable insight in the Japanese perspective and success in treating gastric cancer. Included in the appendix is an extensive tabular analysis of the gastric cancer database at the Cancer Institute Hospital of Tokyo. Probably the largest such database in the world from a single institution, the analyses present the state of the art in treatment of gastric cancer. Front Matter....Pages I-XIII Front Matter....Pages 1-1 Success of Adjuvant Chemotherapy Trials for Gastric Cancer....Pages 3-6 Randomized Controlled Trials on Adjuvant Therapy for Gastric Cancer: Japanese Experience....Pages 7-16 Multimodality Therapy for Completely Resected (R0) Gastric Cancer (Excluding Japanese Trials)....Pages 17-26 Meta-Analysis of Adjuvant Chemotherapy Trials for Gastric Cancer at the Cancer Institute Hospital, Tokyo....Pages 27-31 Adjuvant Chemotherapy of Gastric Cancer: JCOG Experience....Pages 32-41 Front Matter....Pages 43-43 Activated Carbon Particles Adsorbing Mitomycin C Used Against Peritoneal Carcinomatosis in Gastric Cancer....Pages 45-50 Control of Peritoneal Dissemination with Sequential Methotrexate and 5-Fluorouracil....Pages 51-57 Intraperitoneal Chemotherapy with Mitomycin C or Cisplatin....Pages 58-65 Usefulness of Intraperitoneal Administration of Cisplatin Using a Reservoir for Advanced Gastric Cancer Complicated by Peritoneal Dissemination....Pages 66-70 Peritonectomy as a Treatment Modality for Patients with Peritoneal Dissemination from Gastric Cancer....Pages 71-80 Front Matter....Pages 81-81 Management of Liver Metastases....Pages 83-89 Control of Liver Metastasis by Intrahepatic Chemotherapy with Angiotensin II....Pages 90-94 Front Matter....Pages 95-95 Neoadjuvant Chemotherapy with FLEP Regimen for Incurable Gastric Cancer....Pages 97-103 Case Report of Pathological Complete Remission with FLEP Therapy....Pages 104-107 Neoadjuvant Chemotherapy with FLEP Therapy for Advanced Gastric Cancer: Evaluation of Intraaortic and Intravenous FLEP Infusions....Pages 108-112 Front Matter....Pages 113-113 Rationale for Neoadjuvant Chemotherapy for Advanced Gastric Cancer....Pages 115-121 Multimodality Therapy of Local-Regional Gastric Carcinoma....Pages 122-125 Histopathological Effect of Preoperative Chemotherapy Using Oral 5-Fluorouracil in Patients with Operable Gastric Cancer....Pages 126-130 Neoadjuvant Chemotherapy of Gastric Cancer with UFT....Pages 131-140 Neoadjuvant Systemic Chemotherapy for Advanced Gastric Cancer with Noncurative Clinical Factors....Pages 141-147 Front Matter....Pages 113-113 New Strategy for the Treatment of Advanced or Recurrent Gastric Carcinoma: Neoadjuvant Immunochemotherapy of FLPO Regimen (5-FU, Leucovorin, CDDP, and OK-432)....Pages 148-153 Intraoperative Local Infusion Chemotherapy for Advanced Gastric Cancer....Pages 154-160 Front Matter....Pages 161-161 Future Clinical Trial of Adjuvant Chemotherapy with Sensitivity Test....Pages 163-169 Angiogenesis and Angiogenic Factors of Gastric Cancer....Pages 170-176 Intratumoral Angiogenesis and Micrometastasis in Bone Marrow of Patients with Gastric Cancer....Pages 177-182 Targeting Chemotherapy of Peritoneally Disseminated Gastric Cancer with Monoclonal Antibody-Drug Conjugates....Pages 183-186 Future Perspectives of Gene Therapy for Gastric Cancer....Pages 187-193 Back Matter....Pages 195-272